Navigation Links
Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
Date:7/11/2011

BERLIN, July 11, 2011 /PRNewswire/ -- John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Eli Lilly and Company (NYSE: LLY), today urged that biopharmaceuticals be included in transatlantic trade and economic discussions.  Lechleiter participated in the American Council on Germany's conference on "The Transatlantic Partnership in the 21st Century," joining U.S. Fed Chairman Paul Volcker; German State Secretary in the Federal Finance Ministry Jorg Asmussen; and Handlesblatt editor-in-chief Gabor Steingart in a panel discussion.    

"Biopharmaceutical innovation has enormous global economic and social benefits," said Lechleiter. "New medicines are one of the most cost-effective investments we can make to improve health care and enable more efficient use of health care budgets. The whole world has a stake in policies in Europe and America that promote innovation and trade to address the vast unmet medical needs of growing and aging populations."  

Even with these benefits, biopharmaceutical innovation is very susceptible to the political environment – both nationally and internationally.  Lechleiter explained that responses to short-term cost pressures by government payers are hampering the sector, citing recent reforms in Germany as an example.  

"We must ensure that health care reform in our countries will help promote biopharmaceutical innovation and not undermine it," said Lechleiter.  "Health care reform should focus on creating value through the system — and that means promoting innovation and efficiency.  Even the absolute requirements of our sector in global markets – intellectual property protection, supply chain security and anti-counterfeiting measures – are far from secure."

To spur trans-Atlantic trade in pharmaceuticals and maintain medical in
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... of the results of the Company,s 72-patient, placebo-controlled ... drops) for the treatment of dry eye patients ... ) model.  The exploratory study was completed in ... disseminated by the Company in a press release, ...
(Date:5/22/2015)... -- According to a new market research ... Services), by Test Type (Indirect, Enzyme-based, Reactive Oxygen Species ... Users - Global Forecast to 2020", published by MarketsandMarkets, the ... $736.85 Million by 2020 from $452.36 Million in 2015, ... Browse 71 market data Tables and 90 Figures spread ...
(Date:5/22/2015)... , May 22, 2015   InspireMD, Inc. ... stent embolic protection systems ("EPS"), today announced that its CGuard ... lead by principle investigator Prof. Piotr Musialek , at ... Paris, France . PARADIGM, an ... R cutaneous c A roti D revascularization I ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
... 60 percent of moderate to severe patients achieved ... remission at Week 10,in data from a 54-week ... (ACG) Annual Scientific Meeting, ORLANDO, Fla., Oct. ... prospective study investigating endoscopic improvement in Crohn,s,disease (CD) ...
... Pharmacokinetic Characteristics of Naltrexone SR Associated with ... Better Tolerability in Clinical Trials ... OREX ), a biopharmaceutical company focused on the ... presented,data showing the investigational drug, Contrave(R) (naltrexone SR /,bupropion ...
Cached Medicine Technology:CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5
(Date:5/22/2015)... London, UK (PRWEB) May 22, 2015 ... the leading treatment option for chronic obstructive pulmonary ... UK’s GlaxoSmithKline plc and AstraZeneca plc as well ... for market share and position. But will market ... from the already well-entrenched products to completely new ...
(Date:5/22/2015)... Carnegie Science Center and Allegheny ... to develop BodyTech, a dynamic, three-pronged health and science ... new exhibit at the Science Center called BodyWorks, the ... traveling science show, Anatomy Adventure, which will hit the ... to explore a wide range of topics surrounding health ...
(Date:5/22/2015)... Power Systems is proud to announce the sponsorship ... Drobeck is in his second year of racing in the ... Missoula Fire Department in Missoula, MT. He entered the triathlon ... his career, he has had 15 1st Place finishes. In ... finishes in all seven of his 2014 races, including two ...
(Date:5/22/2015)... May 22, 2015 The ... Dental announces that they are now offering complimentary ... other dental treatments. At consultations, patients can discuss ... regarding what certain treatments can achieve and whether ... during this initial appointment. If treatments are chosen, ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 A ... at the American Society of Clinical Oncology (ASCO)’s ... improved survival rates for those patients who received ... regimen of pemetrexed/cisplatin. Bevacizumab (Avastin® Genentech, Inc.) is ... and it is already routinely used to treat ...
Breaking Medicine News(10 mins):Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2
... Pure Power Mouthguard ... , ... December 4, 2009 -- Miami dentist Dr. H.A. Nassery contributes to local athletic ... to patients. He successfully diagnosed and treated Ashley Kimmel, a student at Miami Country Day ...
... 2-D images represent, researchers say , FRIDAY, Dec. 4 ... monkeys they know, proving that they can both detect ... them before, researchers report. , The study also shows ... a photograph, the scientists authors noted. , The findings, ...
... However, benefits are not clear enough to recommend its ... News) -- Cancer patients, glaucoma patients and others can ... shows that it can help multiple sclerosis (MS) patients ... hallmark of the debilitating autoimmune disease. , "The therapeutic ...
... , LOS ANGELES, Dec. 4 Yogen Fruz , the ... holiday themed "NUmixes" -- Yog-Nog and Mint Chocolate ... unveiled at Yogen Fruz stores across North America. Yogen Fruz,s low-calorie ... dessert alternative to indulge in this holiday season. , ...
... , BOSTON and HOUSTON, Dec. 4 AES Annual ... announced today that Vagus Nerve Stimulation (VNS) Therapy , the ... will be featured in 14 presentations at the American Epilepsy ... Hynes Convention Center in Boston, Massachusetts. , Robert Elliott, ...
... , ... InhibOx, a leading developer of novel ... MolPort, an innovator in rare chemical trading.,MolPort focuses on developing rare ... we provide this database and its updates to computational chemists at ...
Cached Medicine News:Health News:Miami Dentist Dr. H.A. Nassery Treats Local Teen Golf Star and Helps Improve Her Performance 2Health News:Review Finds Marijuana May Help MS Patients 2Health News:Review Finds Marijuana May Help MS Patients 3Health News:Yogen Fruz Introduces New Holiday Flavors: Yog-Nog and Mint Chocolate Chip 2Health News:NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 2Health News:NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 3Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 3
The CryoSurgery console is the control center for CryoCath's surgical probe. It is a modular system made up of a console control unit and a tank dolly system. The system can be used as a unit or in s...
... developed a minimally invasive cryocatheter to ... delivers a very high level of ... site precision, minimal tissue disruption, and ... ,Freezor is a flexible, single-use, minimally ...
The Valve Mapper Steerocath-Dx has a unique "peanut" shaped tip. It is designed to conform to the anatomy during mapping procedures. Both 8F/8mm and 8F/6mm tips are available....
... The PORTERFIELD catheter incorporates six electrodes which ... from a single catheter. Positioned in the ... while recording atrial electrograms. The catheter may ... apex for atrial recording and ventricular pacing ...
Medicine Products: